AB0715 THE LONG-TERM PROGNOSTIC VALUE OF THE “2022 ACR/EULAR CLASSIFICATION CRITERIA FOR TAKAYASU ARTERITIS”: DATA FROM A LARGE MONOCENTRIC COHORT

Background The “2022 classification criteria“ for Takayasu arteritis (TAK) have been developed the purpose of classifying patients with TAK. These criteria provide a score from 0 to 22; ≥5 allows classify patient. Objectives To investigate whether criteria” correlates long-term outcomes Methods Data TAK followed up ≥1 year and evaluated at least once within last our Vasculitis Clinic were reviewed. For each patient, provided by baseline was calculated following 24, 60, 120 months evaluated: glucocorticoid (GC) suspension, introduction conventional disease-modifying anti-rheumatic drug (cDMARD), biologic DMARD (bDMARD), need vascular procedure, total number bDMARDs received. Correlation these different thresholds (scores ≥5, ≥6, ≥7) evaluated. Statistical tests performed as appropriate. Results included (103 women, 87.3%); mean follow-up duration 154±113.8 (24 months, n=110, 60 n=88, n=60). Mean age diagnosis 37.3±13.6 years. 112 (93%) classified having (mean score, 9.5±3). Seven (5.8%) only treated GC; 110 (91.6%) received one cDMARD (mean, 1.6±1), after 23.6±61.1 months; 80 (66.7%) bDMARD 1.2±1.5), 40.1±64.5 months. GCs suspended in 44 (36.7%), 102.3±93.7 Forty-four (36.7%) underwent procedure 0.9±1.5). No significant correlation between five found all three timepoints (Table 1). GC csDMARD or bDMARD, ≥7 A both scores ≥6 (1.3±1.5 vs 0.6±0.8, p=0.045, 1.3±1.6 0.6±0.7, p=0.035, respectively). Conclusion Although TAK“ do not seem correlate prognosis, cohort we that higher (≥6) is associated during follow-up. This suggests might allow identify more refractory disease. preliminary data be replicated larger cohorts. References [1]Grayson PC, et al. Ann Rheum Dis. 2022;81(12):1654-1660 Table 1. Correlations basline suspension Vascular 24 (n=110 ) Total 10.3±2.8 10.6±2.3 p=0.65 9.7±2.9 9.6±3.4 p=0.89 9.5±2.9 9.8±3.1 10.1±3.1 9.5±3.1 p=0.28 Score n=103 11/103 0/7 p=0.99 77/103 5/7 46/103 3/7 32/103 2/7 n=99 11/99 0/11 p=0.59 75/99 7/11 p=0.47 45/99 4/11 p=0.75 31/99 3/11 n=96 11/96 0/14 p=0.35 73/96 9/14 p=0.54 43/96 6/14 30/96 4/14 (n=88 Totale 9.6±2.5 10±3.1 p=0.29 10.1±2.8 9.4±3.5 p=0.53 10.2±2.8 9.8±3.2 p=0.83 9.9±2.9 p=0.61 n=84 17/84 0/4 67/84 3/4 46/84 2/4 33/84 n=81 16/81 1/7 66/81 4/7 p=0.15 45/81 p=0.69 32/81 n=80 16/80 1/8 66/80 4/8 p=0.05 45/80 3/8 p=0.46 32/80 (n=60 9.6±3.1 10.5±2.9 10.4±2.7 9.9±3.8 p=0.87 10.5±2.8 p=0.68 10.2±3.3 p=0.90 N=58 14/58 1/2 p=0.44 45/58 p=0.42 27/58 26/58 2/2 p=0.21 n=55 13/55 2/5 44/55 p=0.08 26/55 25/55 3/5 p=0.66 n=54 13/54 2/6 p=0.64 43/54 3/6 p=0.13 26/54 p=0.67 25/54 Acknowledgements: NIL. Disclosure Interests None Declared.